Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial [0.03%]
在以东亚人群为主的超重或肥胖人群中，每周一次2.4毫克司美格鲁特用于体重管理的有效性和安全性（STEP 7）：一项双盲、多中心、随机对照试验
Yiming Mu,Xiaolei Bao,Freddy G Eliaschewitz et al.
Yiming Mu et al.
Background: Data on the benefits of the once weekly GLP-1 receptor agonist semaglutide 2·4 mg for weight management in people from east Asia are insufficient. The objective of this study was to determine the efficacy and...
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial [0.03%]
肥胖的胰高血糖素和GLP-1受体双重激动剂survodutide：一项随机、双盲、安慰剂对照、剂量探索的二期试验
Carel W le Roux,Oren Steen,Kathryn J Lucas et al.
Carel W le Roux et al.
Background: Obesity is a widespread and chronic condition that requires long-term management; research into additional targets to improve treatment outcomes remains a priority. This study aimed to investigate the safety, ...
Stephen C Bain,David M Williams
Stephen C Bain
Bernard Khoo,Tricia M-M Tan
Bernard Khoo
Sanjay Rajagopalan,Robert D Brook,Pedro R V O Salerno et al.
Sanjay Rajagopalan et al.
The Global Burden of Disease assessment estimates that 20% of global type 2 diabetes cases are related to chronic exposure to particulate matter (PM) with a diameter of 2·5 μm or less (PM2·5). With 99% of the global population residing i...
PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial [0.03%]
口服给药的NNC0385-0434对高胆固醇血症患者PCSK9的抑制作用：一项随机、双盲、安慰剂对照和阳性药物对照二期临床试验
Michael J Koren,Olivier Descamps,Yoshiki Hata et al.
Michael J Koren et al.
Background: Currently available injectable drugs that target proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce serum LDL cholesterol and improve cardiovascular outcomes. This phase 2 study assessed NNC0385-0434...
A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis [0.03%]
垂体肿瘤的临床分类在治疗和预后中的指导作用提案
Ken K Y Ho,Maria Fleseriu,John Wass et al.
Ken K Y Ho et al.
No comprehensive classification system that guides prognosis and therapy of pituitary adenomas exists. The 2022 WHO histopathology-based classification system can only be applied to lesions that are resected, which represent few clinically ...